New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:28 EDTREGNRegeneron reports 85.5% of patients achieve EASI-50 in study of dupilumab
Regeneron disclosed in a regulatory filing that on March 4, at the annual meeting of the American Academy of Allergy, Asthma & Immunology, data from a Phase 2a trial evaluating dupilumab, a human monoclonal antibody, in patients with atopic dermatitis were presented at an oral session by Prof. Diamant Thaci. The data presented in slides show 85.5% of patients showed a reduction of EASI-50 over 12 weeks and EASI-75 reduction was seen in 61.8% of patients over 12 weeks.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
05:16 EDTREGNRegeneron, Sanofi announce positive Phase 2 top-line dupilumab results
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps, or CSwNP, who did not respond to intranasal corticosteroids. In the study, dupilumab resulted in a statistically-significant improvement in the size of nasal polyps, as measured by endoscopic Nasal Polyp Score, the primary endpoint of the study. Statistically significant improvements in all secondary efficacy endpoints were also observed, including objective measures of sinusitis by CT scan, nasal air flow, and patient-reported symptoms. In a pre-specified exploratory analysis, dupilumab-treated patients who also had asthma demonstrated significant improvements in asthma control. The safety profile was consistent with previous studies. The most common AEs with dupilumab were injection site reactions, nasopharyngitis, oropharyngeal pain, epistaxis, headache and dizziness.
September 29, 2014
07:26 EDTREGNInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
08:59 EDTREGNSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 22, 2014
05:17 EDTREGNRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 16, 2014
07:31 EDTREGNRegeneron's EYLEA Injection granted designation for treatment of retinopathy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use